Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-22-062651)

Filing Details

Accession Number:: 0001209191-22-062651
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-12-23 17:10:18
Reporting Period:: 2022-12-01

Accepted Time:: 2022-12-23 17:10:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1087294	Cumberland Pharmaceuticals Inc	CPIX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1632384	C Joseph Galante	2525 West End Avenue Suite 950 Nashville TN 37203		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-12-01	65	$2.33	55,871	No	4	P	Direct
Common Stock	Acquisiton	2022-12-02	65	$2.31	55,936	No	4	P	Direct
Common Stock	Acquisiton	2022-12-05	65	$2.19	56,001	No	4	P	Direct
Common Stock	Acquisiton	2022-12-06	65	$2.19	56,066	No	4	P	Direct
Common Stock	Acquisiton	2022-12-07	65	$2.18	56,131	No	4	P	Direct
Common Stock	Acquisiton	2022-12-08	65	$2.19	56,196	No	4	P	Direct
Common Stock	Acquisiton	2022-12-09	65	$2.15	56,261	No	4	P	Direct
Common Stock	Acquisiton	2022-12-12	65	$2.14	56,326	No	4	P	Direct
Common Stock	Acquisiton	2022-12-13	120	$2.18	56,446	No	4	P	Direct
Common Stock	Acquisiton	2022-12-14	120	$2.21	56,566	No	4	P	Direct
Common Stock	Acquisiton	2022-12-15	60	$2.24	56,626	No	4	P	Direct
Common Stock	Acquisiton	2022-12-16	100	$2.22	56,726	No	4	P	Direct
Common Stock	Acquisiton	2022-12-19	250	$2.21	56,976	No	4	P	Direct
Common Stock	Acquisiton	2022-12-20	200	$2.31	57,176	No	4	P	Direct
Common Stock	Acquisiton	2022-12-21	180	$2.22	57,356	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.